Role of plasma homocysteine and lipoprotein (a) in coronary artery disease

British Journal of Biomedical Science

Volumn 61, Issue 2, 2004, Pages 78-83

  Barghash, N A ^a,b   Elewa, S M ^a   Hamdi, E A ^a   Barghash, A A ^a   El Dine, R ^a  

^a ALEXANDRIA UNIVERSITY   (Egypt)

^b NONE   (Egypt)

Author keywords

Coronary disease; Folic acid; Homocysteine; Lipoprotein(a); Plasminogen activator inhibitor 1

Indexed keywords

FOLIC ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LIPID; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD LEVEL; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; FOLIC ACID BLOOD LEVEL; HUMAN; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 3042795411     PISSN: 09674845     EISSN: None     Source Type: Journal    
DOI: 10.1080/09674845.2004.11732648     Document Type: Article

References (43)

1. Ross RS, Gohn PF, Braunwald E. Ischaemic heart disease. In: Isselbacher KJ, et al., eds. Harrison's Principles of internal medicine (9th edn). Tokyo: McGraw-Hill Kogakushu, 1980: 1116-24.
2. Cheitlin MD, Sokolow M, McIlory MB. Coronary heart disease. In: Clinical cardiology (6th edn). London: Lange Medical Publication, 1993: 147.
3. Woo KS, Qiao M, Chook P et al. Homocysteine, endothelial dysfunction and coronary artery disease: emerging strategy for secondary prevention. J Card Surg 2002; 17: 432-5.
4. Bogaty P, Robitaille NM, Solymoss S et al. Atherogenic, hemostatic and other potential risk markers in subjects with previous isolated myocardial infarction compared with long-standing uncomplicated stable angina. Am Heart J 1998; 136: 884-93.
5. Devlin T. Metabolism of the individual amino acids. In: Devlin T, ed. Textbook of biochemistry with clinical correlations (4th edn). Chichester: Wiley, 1997: 563-626.
6. Robert K, Peter A, Victor W, eds. Harper's biochemistry (25th edn). London: Appleton & Lange, 2000: 323-46, 627-41.
7. Allen RH et al. Water-soluble vitamins, hyperhomocysteinemia and risk for vascular disease and thrombosis. Clin Hemost Rev 1995; 9(11): 9.
8. Klimer S. Homocysteine, folate, vitamin B2 and cardiovascular disease. JAMA 1998; 279: 392-3.
9. Wilcken DEL. Homocysteine, smoking and vascular disease. Eur Heart J 2002; 20(23): 1559-60.
10. McCully KS. Macromolecular basis for homocysteine-induced abnormalities of proteoglycan structure in arteriosclerosis. Am J Pathol 1972; 59: 181-93.
11. Kircher T, Sinzinger H. Homocysteine - relevant for atherogenesis. Wien Klin Wochenschr 2000; 112(12): 523-32.
12. Daniel A, Selvi P, Steingrimur S et al. Characterization of the binding of different conformational forms of PAI-1 to vitronectin. Implications for the regulation of pericellular proteolysis. J Biol Chem 1997; 272: 7676-80.
13. Lawn RM, Kare Berg. Lipoprotein (a) and athersclerosis. Ann Intern Med 1991; 115: 209-18.
14. Delplanque B, Beamont V, Lemort N, Beaunont JL. Lp(a) levels and anti-estrogen antibodies in women with and without thrombosis in the course of oral contraception. Atherosclerosis 1993; 100: 183-8.
15. Frantzen F, Faaren AL, Alfheim I, Nordhei AK. An enzyme conversion immunoassay for determining total homocysteine in plasma or serum. Clin Chem 1998; 44: 311-6.
16. 12 and folic acid in serum evaluated. Clin Chem 1982; 28: 2161-5.
17. Declerck PJ, Alessi MC, Verstreken M, Kruithof EK, Vague I, Collen D. Measurement of plasminogen activator inhibitor-1 in biological fluids with a murine monoclonal antibody-based, enzyme-linked immunosorbent assay. Blood 1988; 71: 220-5.
18. Erwan M. Limits of lipoprotein (a) detection by polyacrylamide gel electrophoresis. Scand J Clin Lab Invest 1990; 50: 917-8.
19. Carr TP, Andresen CJ, Rudel LL. Enzymatic determination of triglycerides, free cholesterol, and total cholesterol in tissue lipid extracts. Clin Biochem 1993; 26: 39-42.
20. Allian CC, Poon IS, Chan CGS, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. Clin Chem 1974; 20: 470-5.
21. Boldo Enzi G, Baroni L, Piccoli A, Baiccchi MR, Fellin R. Cholesterol determination in HDL1, HDL2, and HDL3 fractions after polyanion precipitation: a comparison between chemical extractive and totally enzymatic procedures. Clin Chim Acta. 1985; 146: 81-6.
22. Demacker PN, Brenninkmeijer BJ, Jansen AP, Laar A. Five methods for determining LDL-cholesterol compared. Clin Chem 1984; 30: 1797-800.
23. Kullo IJ, Gau GT, Tajik AJ. Novel risk factors for atherosclerosis. Mayo Clin Proc 2000; 75(4): 369-80.
24. Conri C, Constans J, Parrot F, Skopinski S, Cipriano C. Homocysteinemia: role in vascular disease. Press Med 2000; 29(13): 737-41.
25. Chambers JC, McGregor A, Jean-Marie J, Kooner JS. Acute hyperhomocysteinemia and endothelial dysfunction. Lancet 1998; 351: 36-7.
26. Krumdieck CL, Prince CW. Mechanisms of homocysteine toxicity on connective tissues: implications for the morbidity of aging. J Nutr 2000; 130(2S Suppl): 365S-8S.
27. Jakubowski H, Zhang L, Bardeguez A, Aviv A. Homocysteine thioloctone and protein homocysteinylation in human endothelial cells: implications for atherosclerosis. Circ Res 2000; 87: 45-51.
28. Dardik R, Varon D, Tomarin I et al. Homocysteine and oxidized low-density lipoprotein enhanced platelet adhesion endothelial cells under flow conditions: distinct mechanisms of thrombogenic modulation. Thromb Haemost 2000; 83(2): 338-44.
29. Al-Obaidi MK, Philippou H, Stubbs PJ et al. Relationships between homocysteine, factor VIIa, and thrombin generation in acute coronary syndromes. Circulation 2000; 101(4): 372-7.
30. 12 and DNA damage in coronary artery disease. Hum Genet 2003; 112: 171-7.
31. Glueck CJ, Fontaine RN, Gupta A, Alasmi M. Myocardial infarction in a 35-year-old man with homocysteinemia, high PAI activity and resistance to activated protein C. Metabolism 1997; 46: 1470-2.
32. Robinson K, Arheart K, Refsum H et al. The European Comac Group. Low circulating folate and vitamin B6 concentrations: risk factors for stroke, peripheral vascular disease and coronary artery disease. Circulation. 1998; 97: 437-43.
33. 12, folate and Thai coronary artery disease patients. J Med Assoc Thai. 2000; 83: 536-42.
34. Klerk M, Verhoef P, Clarke R et al. MTHER Studies Collaboration Group. 677C→T polymorphism and risk of coronary heart disease. JAMA 2002; 288: 2023-31.
35. Willems FF, Aengevaeren WR, Boers GH, Blom Hj, Verheugt FW. Coronary endothelial function in hyperhomocysteinemia: improvement after treatment with folic acid and cobalamin in patients with coronary artery disease. J Am Coll Cardiol 2002; 40(4): 766-72.
36. Newman PE. Can reduced folic acid and vitamin B12 levels cause deficient DNA methylation producing mutations which initiate atherosclerosis? Med Hypotheses 1999; 53: 421-4.
37. Soeki T, Tamura Y, Fukuda N, Ito S. Plasma and platelet PAI-1 in patients with acute myocardial infarction. Jpn Circ J 2000; 64: 547-53.
38. Sobel BE. Increased plasminogen activator inhibitor-1 and vasculopathy: a reconcilable paradox. Circulation 1999; 99: 2496-8.
39. Schaefer EJ, Lamon-Fava S, Jenner JL et al. Lipoprotein(a) levels and risk of coronary heart disease in men. The lipid research clinics coronary primary prevention trial. JAMA 1994; 271: 999-1003.
40. Sun H, Unoki H, Wang X et al. Lipoprotein(a) enhances advanced atherosclerosis and vascular calcification in WHHL transgenic rabbits expressing human apolipoproteine(a). J Biol Chem 2002; 277: 47486-92.
41. Hart-Camejo, Paredes S, Masana L et al. Elevated levels of small, low-density lipoprotein with high affinity for arterial matrix components in patients with rheumatoid arthritis. Arth Rheum 2001; 44: 2761-7.
42. Maher VMG, Brown BG, Marcovina SM, Hillger LA, Zhao XQ, Albers JJ. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of Lipoprotein(a). JAMA 1995; 274: 1771-4.
43. Kygiyama K, Ota Y, Takazoe K et al. Circulating levels of secretary type I phospholipase A2 predict coronary events in patients with coronary artery disease. Circulation 1999; 100: 1280-4.